AstraZeneca

Results of the trial, which involved more than 32,000 volunteers, showed two doses of the vaccine administered four weeks apart had an efficacy of 79% at preventing symptoms of COVID-19.

The two countries joined a number of other European nations that have temporarily suspended the shot after several people reportedly developed blood clots after receiving it.

The pharmaceutical company made the announcement on Monday, saying that one dosing regimen showed the vaccine was 90% effective in preventing infection.

Medications for heartburn called proton pump inhibitors are linked to a higher risk for chronic kidney disease, according to a study. It's the latest in a growing list of worries with these drugs.